Brief: Nanobiotix Announces Oral Presentation Of Final Results From Early-Stage Dose Expansion Study Of Head And Neck Cancer Treatment
29/09/2023 21:41
Sept 29 (Reuters) - Nanobiotix SA NANOB.PA :
* NANOBIOTIX ANNOUNCES ORAL PRESENTATION OF FINAL RESULTS
FROM A
PHASE 1 DOSE EXPANSION STUDY EVALUATING NBTXR3 IN HEAD AND NECK
CANCER AT THE 65TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR
RADIATION ONCOLOGY
Source text for Eikon: ID:nGNXbB67WR
Further company coverage: NANOB.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nanobiotix SA
See all newsBrief: Nanobiotix S.A. H1 Net Income EUR -34.3 Million
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Brief: Nanobiotix Q1 Cash And Cash Equivalents Of €42.1 Mln
Brief: NANOBIOTIX Announces Closing Of Global Offering